Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0524A (Tredaptive) in Heterozygous Familial Hypercholesterolemia
NCT00384293Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of laropiprant in heterozygous familial hypercholesterolemia (HeFH) (2 arms), sponsored by Merck & Co. Primary endpoint: Change in Mean Carotid Intima Media Thickness at 96 weeks. Started Sep 2006; status: terminated.
02
Drugs
laropiprant
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on NCT00384293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00384293.